AstraZeneca Shares Plunge After Wainua Trial Failure Raises Pipeline Doubts

AstraZeneca stock fell sharply as investors question the credibility of its high-valuation drug pipeline following a failed trial.

Carried by 3 publishers across 3 articles; the full record rides under the article.

Truth Foundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.